Rhythm Pharmaceuticals (RYTM) Stock

BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of results from its Phase 3 VENTURE trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, in children between the ages of 2 and younger than 5 years old with Bardet Biedl syndrome (BBS) or pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency. The data are published in the peer-reviewed journal  The Lancet Diabetes & Endocrinology .

BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in fireside chats at two upcoming investor conferences:

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Q3 2024 Earnings Conference Call November 5, 2024 5:00 PM ET Company Participants David Connolly - Head of Investor Relations and Corporate Communications David Meeker - Chairman, President and Chief Executive Officer Jennifer Lee - Executive Vice President and Head of North America Yann Mazabraud - Executive Vice President and Head of International Hunter Smith - Chief Financial Officer Conference Call Participants Philip Nadeau - TD Cowen Corinne Johnson - Goldman Sachs Group, Inc. Seamus Fernandez - Guggenheim Securities Dae Gon Ha - Stifel, Nicolaus & Company, Inc. Whitney Ijem - Canaccord Genuity Corp. Jeff Hung - Morgan Stanley Tazeen Ahmad - Bank of America Merrill Lynch Joseph Stringer - Needham & Company Raghuram Selvaraju - H.C. Wainwright & Co. Operator Good day, and thank you for standing by.

Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.80. This compares to loss of $0.76 per share a year ago.

BOSTON, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that on October 4, 2024, the Compensation & Management Development Committee of Rhythm's Board of Directors granted inducement restricted stock units, or RSUs, covering an aggregate of 30,050 shares of its common stock to nine new employees.

IMCIVREE is FDA-approved for obesity due to genetic mutations and aims to expand its label to include children as young as 2 years old. The company is also exploring IMCIVREE for hypothalamic obesity in a phase 3 study, with data expected in the 1st half of 2025. Financially, Rhythm has $319.1 million in cash, but may need to raise more funds within the next 12 months.

Rhythm Pharmaceuticals (RYTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

BOSTON, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that on September 11, 2024, the Compensation & Management Development Committee of Rhythm's Board of Directors granted inducement restricted stock units, or RSUs, covering an aggregate of 15,450 shares of its common stock to four new employees.

RYTM gains 8% as FDA accepts Imcivree sNDA seeking label expansion of the drug to treat obesity in kids as young as two years old.